Table 2.
Liver Transaminase Changes from TDF-TAF Switch to 6-Month Follow-Up
| AST (IU/L) | ALT (IU/L) | ||||
|---|---|---|---|---|---|
| Median, IQR | P* | Median, IQR | P* | ||
| Overall | 190 | −1 (−5 to 2) | 0.004 | −2 (−7 to 3) | 0.0004 |
| HCV-Ab | |||||
| Neg | 144 | −1 (−4 to 3) | 0.08 | −1 (−7 to 3) | 0.01 |
| Pos | 46 | −2 (−9 to 1) | 0.009 | −3 (−11 to 2) | 0.0007 |
| HBsAg | |||||
| Neg | 173 | −1 (−5 to 2) | 0.003 | −2 (−8 to 2) | 0.0003 |
| Pos | 17 | 0 (−4 to 4) | 0.97 | 1 (−6 to 4) | 0.86 |
| HCV-Ab/HBsAg | |||||
| Neg/neg | 133 | −1 (−5 to 2) | 0.03 | −2 (−7 to 2) | 0.003 |
| HCV and/or HBsAg pos. | 57 | −2 (−7 to 2) | 0.08 | −2 (−7 to 3) | 0.05 |
| HCV active infection at baseline | |||||
| No | 178 | −1 (−5 to 2) | 0.004 | −2 (−7 to 3) | 0.005 |
| Yes | 12 | −4 (−18 to 10) | 0.48 | −1 (−27 to 6) | 0.48 |
| Baseline level AST | |||||
| ≤ 40 | 175 | −1 (−4 to 2) | 0.03 | - | - |
| > 40 | 15 | −18 (−23 to −2) | 0.07 | - | - |
| Baseline level ALT | |||||
| ≤ 40 | 162 | - | - | −1 (−6 to 4) | 0.047 |
| > 40 | 28 | - | - | −17 (−32 to −1) | 0.0003 |
Note: *Signed rank test.
Abbreviations: IQR, interquartile range; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HCV-Ab, hepatitis C virus-antibodies; HBsAg, hepatitis B surface antigen.